The reference scenario

Prostate cancer currently ranks second in the most diagnosed forms of cancer among male population in the world. In Italy it is the most common neoplasm among men over 50.

The data is likely to increase, considering important factors such as the progressive aging of the population.

As a consequence, costs are also increasing: if the volume of expenditure due to prostate cancer was almost 17 billion dollars in 2018, by 2023 it will have reached the threshold of 26 billion (source: Europe Prostate Cancer Epidemiology and Patient Flow Analysis – 2018).

To subvert this trend, it is necessary to intervene on the diagnosis and treatment processes, by overcoming the limits established in the current protocols and continuing in the search for new solutions.

In particular, in the diagnostic field there is a need to develop new radiotracers for PET / CT that have greater specificity and sensitivity than those currently in use, such as 18F-Choline.

In the therapeutic field, on the other hand, the approaches are prostatectomy, radiotherapy and androgen deprivation therapy (ADT). However, all of them have strongly impacting collateral effects on the quality of life of the cancer patient, which can be partly mitigated by intervening with specific feeding plans and physical activity.